FOLH1 and neoplasm: Due to the high expression of the prostate-specific membrane antigen (PSMA) in this type of tumor and Lu-177 being an ideal radionuclide for the treatment of micro-metastases (mean range of 670 μm and 0.1–2.2 MeV energies of beta particles), [177Lu]Lu-PSMA-targeted radionuclide therapy is a highly effective therapy for most mCRPC patients.